LENSAR, Inc. Common Stock
LNSRLENSAR, Inc. is a medical technology company specializing in laser systems for ophthalmic surgical procedures, particularly cataract surgery. Known for its advanced laser platforms, the company focuses on improving surgical outcomes and efficiency through innovative laser automation and cutting-edge ophthalmic solutions.
Company News
Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65,...
LENSAR, Inc. announced the termination of its merger agreement with Alcon Research, LLC due to FTC opposition. The companies mutually agreed that obtaining necessary U.S. regulatory approvals was unlikely by the merger's outside date. LENSAR will retain the $10.0 million deposit and plans to focus on expanding its ALLY Robotic Cataract Laser Syst...
LENSAR, Inc. announced that its pending acquisition by Alcon Research, LLC remains under FTC review following a Second Request for Additional Information. The company expects to close the transaction in the first half of 2026, subject to regulatory approval and satisfaction of closing conditions.
SpyGlass Pharma announced the appointment of Elizabeth O'Farrell to its Board of Directors, bringing over 30 years of healthcare industry experience. She will serve as an Independent Director and Chair of the Audit Committee, supporting the company's advancement of its Drug Delivery Platform for glaucoma management.
LENSAR reported strong Q2 2025 performance with 18 ALLY Robotic Cataract Laser Systems placed, 23% increase in worldwide procedure volumes, and continued progress on its proposed merger with Alcon. Total revenue increased 10% to $13.9 million, with net loss improving to $1.8 million.
